Cytokinetics, Incorporated (CYTK) |
|
29.46 -1.34 (-4.35%)
|
09-29 16:00 |
|
Open: |
31.01 |
Pre. Close: |
30.8 |
|
High:
|
31.09 |
Low:
|
29.25 |
|
Volume:
|
1,689,206 |
Market Cap:
|
2,828(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:51 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 39.7 One year: 43.33 |
| Support: |
Support1: 28.95 Support2: 24.09 |
| Resistance: |
Resistance1: 33.99 Resistance2: 37.09 |
| Pivot: |
32.27 |
| Moving Average: |
MA(5): 30.03 MA(20): 33.19
MA(100): 34.64 MA(250): 38.5 |
| MACD: |
MACD(12,26): -1.2 Signal(9): -0.7 |
| Stochastic oscillator: |
%K(14,3): 10.8  %D(3): 7.5 |
| RSI: |
RSI(14): 31.3 |
| 52-week: |
High: 52.4 Low: 28.95 |
| Average Vol(K): |
3-Month: 811 (K) 10-Days: 1,008 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CYTK ] has closed above bottom band by 14.7%. Bollinger Bands are 85.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
31.16 - 31.32 |
31.32 - 31.44 |
|
Low:
|
28.84 - 29.04 |
29.04 - 29.21 |
|
Close:
|
29.18 - 29.48 |
29.48 - 29.73 |
|
Company Description |
|
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California. |
Headline News |
Thu, 28 Sep 2023
Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program - Yahoo Finance
Thu, 21 Sep 2023
Macquarie Group Ltd. Cuts Position in Cytokinetics, Incorporated ... - MarketBeat
Wed, 20 Sep 2023
Prelude Capital Management LLC Acquires Position in Cytokinetics ... - Best Stocks
Tue, 19 Sep 2023
Prelude Capital Management LLC Invests $257000 in Cytokinetics ... - MarketBeat
Mon, 18 Sep 2023
Duality Advisers LP Buys Shares of 26469 Cytokinetics ... - MarketBeat
Fri, 15 Sep 2023
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
96 (M) |
|
% Held by Insiders
|
9.521e+007 (%) |
|
% Held by Institutions
|
0.8 (%) |
|
Shares Short
|
10,090 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.7522e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-4 |
|
Return on Assets (ttm)
|
843.1 |
|
Return on Equity (ttm)
|
-38.9 |
|
Qtrly Rev. Growth
|
9.95e+006 |
|
Gross Profit (p.s.)
|
-133.79 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.97595e+008 |
|
Qtrly Earnings Growth
|
-5.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-426 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.6 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-6.29 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.161e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
